Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

A. Wells, Samuel; G. Robinson, Bruce; F. Gagel, Robert; Dralle, Henning; A. Fagin, James; Santoro, Massimo; Baudin, Éric; Elisei, Rossella; Jarząb, Barbara; R. Vasselli, James; Read, Jessica; Langmuir, Peter; J. Ryan, Anderson; Schlumberger, Martin

doi:10.1200/jco.2011.35.5040

Public

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Published in Journal of Clinical Oncology • Oct 25, 2011

Authors:

Samuel A. Wells

Bruce G. Robinson

Robert F. Gagel

Abstract

PURPOSE: There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase ...

Subject

Vandetanib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!